RT Journal Article
SR Electronic
T1 The Prognostic Value of Both Neuron-specific Enolase (NSE) and Cyfra21-1 in Small Cell Lung Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1941
OP 1946
VO 24
IS 3B
A1 SOICHIRO ANDO
A1 MAKOTO SUZUKI
A1 NAOYOSHI YAMAMOTO
A1 TOMOHIKO IIDA
A1 HIDEKI KIMURA
YR 2004
UL http://ar.iiarjournals.org/content/24/3B/1941.abstract
AB Purpose: The aim of this study was to verify the prognostic significance of multiple tumour markers in small cell lung cancer (SCLC). Patients and Methods: We examined seven tumour markers [carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9), squamous cell carcinoma antigen (SCC), neuron-specific enolase (NSE), cancer antigen 125 (CA125), cytokeratin 19 fragment (Cyfra21-1) and Pro-Gastrin-releasing peptide (ProGRP)] in 57 small cell lung cancer (SCLC) patients. Results: Univariate analysis showed that NSE and Cyfra21-1 were independent negative prognostic factors along with gender, therapy and lactate dehydrogenase (LDH). Multivariate analysis showed that both NSE and Cyfra21-1 retained their significance as prognostic factors along with therapy and the respective hazard ratios were 3.918 (p=0.0122) and 2.617 (p=0.0318) among the seven tumour markers. The group with both NSE and Cyfra21-1 positive had a worse prognosis than the only NSE-positive group, with the respective hazard ratios being 10.245 (p=0.0004) and 3.913 (p=0.0123). Conclusion: The group with both of the markers NSE and Cyfra21-1 positive had a worse prognosis than the only NSE-positive group. Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved